Terminated PHASE2 INTERVENTIONAL 2-arm NCT05897372

Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study (WP3)

Sponsor: Iain Bressendorff

Interventions ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib

Updated 4 times since 2023 Last updated: Sep 23, 2024 Started: Aug 1, 2023 Primary completion: Sep 23, 2024 Completion: Sep 23, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow recruitment

Other Diabetic Kidney Disease trials with similar outcome

Browse all Diabetic Kidney Disease trials

Listed as NCT05897372, this PHASE2 trial focuses on Diabetic Kidney Disease and remains terminated or withdrawn. Sponsored by Iain Bressendorff, it has been updated 4 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Oct 2024 — Present [monthly]

Terminated PHASE2

Status: Recruiting → Terminated
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jul 2023 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Iain Bressendorff

Data source: Herlev Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Herlev, Denmark